Global Information
회사소개 | 문의

신약 R&D 파이프라인 데이터베이스 : 연간 구독

R&D Drug Pipeline Database: 1-Year Subscription

리서치사 La Merie Publishing
발행정보 연간구독 상품 코드 302689
페이지 정보 영문
가격
US $ 7,400 ₩ 8,461,100 Web Access (Single User License)
US $ 14,800 ₩ 16,922,300 Web Access (Site License)
US $ 22,200 ₩ 25,383,400 Web Access (Global License)


신약 R&D 파이프라인 데이터베이스 : 연간 구독 R&D Drug Pipeline Database: 1-Year Subscription
발행정보 : 페이지 정보 : 영문

한글목차

본 연간정보 서비스에서는 17,000건 이상의 신약 개발 파이프라인 프로젝트 관련 각종 데이터에 대한 온라인 액세스 권한을 제공하며, 각 프로젝트의 표적·화합물 클래스·제품 카테고리·개발 기업·지역·치료 분야·적응증·개발 단계 등의 데이터를 전해드립니다.

1. 본 데이터베이스의 이점

  • 직감적 이용 가능
  • 24시간 온라인 액세스 가능
  • 구조 검색에 대응
  • 표적, 제품 카테고리, R&D 속도에 초점
  • 경쟁 분석에 최적(기업, 표적, 제품 카테고리)
  • 높은 비용효율과 신속한 벤치마킹 솔루션
  • 라이선싱 후보 특정이 가능

2. 게재 항목

  • 의약품 코드
  • 표적/작용기전
  • 화합물 클래스
  • 제품 카테고리
  • 기업
  • 권역(Territory)
  • 치료 분야
  • 적응증
  • R&D 단계

3. 제품 카테고리

  • 항체
  • 세포
  • DNA
  • 펩티드
  • 단백질
  • RNA
  • 소분자
  • 백신

4. 치료 분야

  • 심장혈관, 혈액, 급성환자 치료
  • 피부과
  • 소화기과
  • 비뇨생식기, 부인과, 신장
  • 감염증, 독소
  • 신진대사, 내분비
  • 신경 및 신경과
  • 안과 및 이비인후과
  • 정형외과, 치과, 마취, 외과
  • 폐, 호흡기
  • 류머티즘, 자기면역

5. 표적 : 사전 설정 스크롤 다운 메뉴 예

  • ADC(Antibody-Drug Conjugates)
  • 항체 및 단백질 매출
  • 세포내 표적(MAGE-A, NY-ESO-1, PRAME 등)
  • Immuno-oncology 표적(PD-1, PD-L1, CTLA-4, LAG-3, TIM-3, 4-1 BB, CD73 등)
  • CAR & TCR Engineered T-Cells and NK Cells
  • Adalimumab (Humira) 바이오시밀러
  • Her2 항체
  • 이중특이성항체
  • 종양 용해성 바이러스(아데노바이러스, 종두증, HSV 등)
  • 에볼라바이러스 백신 및 치료제
  • 응고인자
  • 보툴리눔 신경독소
  • PTH-R 작용제
  • 심혈관계 펩타이드

6. 기술 : 사전 설정 스크롤 다운 메뉴 예

  • Transgenic XenoMouse Antibodies
  • T-Cell Redirecting Bispecific Antibodies
  • Agonistic Antibodies
  • TCR-like Antibodies & Fusion Proteins
  • ADC - Pyrrolobenzodiazepine(PBD)
  • Fc-Fusion Proteins
  • Oligo- and Polyclonal Antibodies
LSH 18.07.03

영문목차

Subscription to La Merie Publishing's proprietary ‘R&D Drug Pieline Database’ provides 24/7 online access to information about more than 23,400 project entries (files) for therapeutic drugs on the market and on investigational drug candidates in research & development. Pre-established and free search functions allow to identify molecules according to their

  • Product category (NCE, antibodies, proteins, DNA, RNA, cells, vaccines, peptides)
  • Technology (e.g.engineered T-cells, antibody-drug conjugate, bispecific antibody)
  • Target (e.g. Her2, BCMA, PD-1, RORgamma)
  • Pipelines (selected by target, therapeutic area, company, technology)
  • Sales (for marketed antibodies, peptides and proteins)
  • R&D Phase (clinical phases, market, preclinical)
  • Territory (countrywise)
  • Therapeutic Area (e.g. infectious, oncology, gastrointestinal)
  • Drug Code/Name (for individual molecules)

Each project is specified for its Target, Therapeutic Area and R&D Phase. Use of the R&D Drug Pipeline Database is intuitive. Data sets of interest can be printed and exported as reports in Excel or Word format. Projects are being updated continuously. The R&D history of each project with online references of information sources can be viewed and printed. Sales figures of major therapeutic antibodies, proteins and peptides on the market are provided.

An advanced search function allows to combine search parameters. A scroll down menu for predefined targets and technologies conveniently selects projects of interest. By clicking on column heads of the project list, projects can be arranged in ascending or descending alphabetical or numerical order, e.g. for phase or company name.

Special Focus of the Database:

  • Immuno-Oncology
  • Biosimilars
  • Antibodies
  • mRNA
  • Engineered Cells
  • Oncolytic viruses
  • Therapeutic Proteins
  • Peptides
  • Vaccines

Prerequisite: Internet access.

Purchase of the subscription provides a 1-year online access to the data of the R&D Drug Pipeline Database. Credentials to access the database will be sent by e-mail within 24 hours after purchase.

Benefits from the R&D Drug Pipeline Database:

  • Intuitive use
  • 24/7 online access
  • Designed for structured searches
  • Focused on targets, product categories and R&D phases
  • Ideal for competitor analysis (companies, targets, product categories)
  • Cost-effective and rapid solution for benchmarking
  • Identification of licensing candidates

Project listing in a tabular format:

  • Drug Codes
  • Target / Mechanism of Action
  • Class of Compound
  • Product Category
  • Company
  • Territory
  • Therapeutic Area
  • Indication
  • R&D Phase

Product Categories:

  • Antibody
  • Cell
  • DNA
  • Peptide
  • Protein
  • RNA
  • Small Molecule
  • Vaccine

Therapeutic Areas:

  • Cardiovascular, blood & acute care
  • Dermatology
  • Gastrointestinal
  • Genitourinary, gynecology & renal
  • Infectious & toxicology
  • Metabolism & endocrine
  • Neurology & psychiatry
  • Oncology
  • Ophthalmolgoy & otorhinolaryngology
  • Orthopedics, dental, anesthesia & surgery
  • Pulmonary & respiratory
  • Rheumatoid & autoimmune

Examples of Predefined Targets of the Scroll Down Menu:

  • Antibody-Drug Conjugates (ADC)
  • Sales of Antibodies & Proteins 2017
  • Intracellular targets (MAGE-A, NY-ESO-1, PRAME etc)
  • Immuno-oncology targets (PD-1, PD-L1, CTLA-4, LAG-3,TIM-3, 4-1BB, CD73 etc)
  • CAR & TCR Engineered T-Cells and NK Cells
  • Adalimumab (Humira) Biosimilars
  • Her2 Antibodies
  • Bispecific Antibodies
  • Oncolytic Viruses (adenovirus, vaccinia, HSV etc)
  • Ebola Virus Vaccines & Therapeutics
  • Coagulation Factors
  • Botulinum Neurotoxins
  • PTH-R Agonists
  • Cardiometabolic Peptides

Examples of Predefined Technologies of the Scroll Down Menu:

  • Transgenic XenoMouse Antibodies
  • T-Cell Redirecting Bispecific Antibodies
  • Agonistic Antibodies
  • TCR-like Antibodies & Fusion Proteins
  • ADC - Pyrrolobenzodiazepine (PBD)
  • Fc-Fusion Proteins
  • Oligo- and Polyclonal Antibodies

Sample Screenshots of R&D Drug Pipeline Database
as of November 12, 2014.

Back to Top
아시아 최대 시장정보 제공
전세계에서 발행되고 있는 모든 시장조사보고서를
다루고 있습니다.
사이트에서 검색되지 않는 보고서도 문의 바랍니다.
 
BCC Research